{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]) as assessed by International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma 2016. PR=response greater than or equal to (\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to less than (\\<) 200 mg per 24 hours. CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates. sCR=complete response below plus normal free light chain (FLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or 8-color, 2 tube multiparametric flow cytometry. VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-component level \\<100 mg/24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"NUMBER","populationDescription":"All treated population","reportingStatus":"POSTED","timeFrame":"Up to 21 months","title":"Percentage of Participants With Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}